CHMP

News

Novo Nordisk nears EU approval of obesity drug Wegovy

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA's human medicines co

News

COVID antibodies from Roche, Celltrion backed for approval i...

The EMA's human medicines committee has recommended approval of Roche's Ronapreve and Celltrion's Regkirona for use in COVID-19, the first antibody-based therapies for coronavirus to be bac

News

Targeting COVID-19 and cancer with immunotherapy advancements

EU backs broader use of Comirnaty as COVID booster than US

The EMA has given the go-ahead to the use of Pfizer and BioNTech's COVID-19 vaccine Comirnaty as a booster for all people aged 18 or more, but says EU member states must decide for themselv

News

Illustration of a nerve cell on a colored background with light effects

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor tanezumab looks to have been dashed after the EMA's human medicines committe

News

AZ closes on Forxiga kidney disease label in EU after nod fr...

AstraZeneca's fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a treatment for chronic kidney disease (CKD) in adults with and without type-2 d

News

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

CHMP backs bluebird bio's gene therapy for rare disease ALD

US biotech bluebird bio has had a challenging time in the last few months, so a recommendation for EU approval of its gene therapy for adrenoleukodystrophy (ALD) will give it a lift.

Novo Nordisk nears EU approval of obesity drug Wegovy

COVID antibodies from Roche, Celltrion backed for approval i...

EU backs broader use of Comirnaty as COVID booster than US

EU panel rejects Pfizer's tanezumab for osteoarthritis pain

AZ closes on Forxiga kidney disease label in EU after nod fr...

CHMP backs bluebird bio's gene therapy for rare disease ALD

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

CHMP

Editor's Picks